0
     

Report Added
Report already added
Erectile Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Erectile Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Erectile Dysfunction - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Erectile Dysfunction (Male Health) pipeline landscape.

Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants, antihistamines and medications to treat high blood pressure, pain or prostate cancer.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Erectile Dysfunction - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Erectile Dysfunction (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Erectile Dysfunction (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 4, 1, 9, 8, 1, 17, 4 and 4 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 2 molecules, respectively.

Erectile Dysfunction (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Erectile Dysfunction (Male Health).
- The pipeline guide reviews pipeline therapeutics for Erectile Dysfunction (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Erectile Dysfunction (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Erectile Dysfunction (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Erectile Dysfunction (Male Health)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Erectile Dysfunction (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Erectile Dysfunction (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Erectile Dysfunction - Overview
Erectile Dysfunction - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Erectile Dysfunction - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Erectile Dysfunction - Companies Involved in Therapeutics Development
AnyGen Co Ltd
Aprogen Inc
Aquestive Therapeutics Inc
Arovella Therapeutics Ltd
Astellas Pharma Inc
Autotelic Bio Inc
Benuvia Therapeutics Inc
Biozeus Pharmaceutical SA
Can-Fite BioPharma Ltd
Chengdu Dikang Pharmaceuticals Co Ltd
Cure Pharmaceutical Holding Corp
Dicot AB
Evincis Bio Inc
Exopharm Ltd
Fabre-Kramer Pharmaceuticals Inc
Farmalider SA
Guangzhou Four-Leaf Clover HealthTech Co Ltd
Hemostemix Inc
Humanetics Corp
ILGEN Inc
Initiator Pharma AS
IntelGenx Corp
Jiangsu Hengrui Medicine Co Ltd
Klaria Pharma Holding AB
Lexaria Bioscience Corp
MannKind Corp
Mezzion Pharma Co Ltd
MicroCures Inc
Mitsubishi Tanabe Pharma Corp
MyX Therapeutics Inc
NAL Pharmaceuticals Ltd
Organicell Regenerative Medicine Inc
Orgenesis Inc
PeLeMed Co Ltd
Pharmicell Co Ltd
Reven Holdings Inc
S1 Biopharma Inc
Seelos Therapeutics, Inc.
Shandong Lukang Pharmaceutical Co Ltd
siRNAgen Therapeutics Corp
Targazyme Inc
Tavanta Therapeutics Inc
Techfields Pharma Co Ltd
Tritech Biopharmaceuticals Co Ltd
Venturis Therapeutics Inc
XuanZhu Biological Technology Co Ltd
Yangtze River Pharmaceutical Group
Erectile Dysfunction - Drug Profiles
ACP-01 - Drug Profile
Product Description
Mechanism Of Action
AGM-175 - Drug Profile
Product Description
Mechanism Of Action
alprostadil - Drug Profile
Product Description
Mechanism Of Action
History of Events
AN-788 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Antisense RNAi Oligonucleotides for Atopy, Erectile Dysfunction, Heart Failure and Psoriasis - Drug Profile
Product Description
Mechanism Of Action
AP-185 - Drug Profile
Product Description
Mechanism Of Action
apomorphine - Drug Profile
Product Description
Mechanism Of Action
avanafil - Drug Profile
Product Description
Mechanism Of Action
History of Events
Biologics for Erectile Dysfunction - Drug Profile
Product Description
Mechanism Of Action
BZ-371 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Cellgram-ED - Drug Profile
Product Description
Mechanism Of Action
History of Events
Cevaris - Drug Profile
Product Description
Mechanism Of Action
History of Events
CF-602 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CMS-203 - Drug Profile
Product Description
Mechanism Of Action
CVBT-141 - Drug Profile
Product Description
Mechanism Of Action
DDCI-01 - Drug Profile
Product Description
Mechanism Of Action
Drug for Erectile Dysfunction - Drug Profile
Product Description
Mechanism Of Action
EVI-200 - Drug Profile
Product Description
Mechanism Of Action
History of Events
fadanafil - Drug Profile
Product Description
Mechanism Of Action
History of Events
FKK-01PD - Drug Profile
Product Description
Mechanism Of Action
genistein - Drug Profile
Product Description
Mechanism Of Action
History of Events
ILG-F - Drug Profile
Product Description
Mechanism Of Action
IPED-2015 - Drug Profile
Product Description
Mechanism Of Action
History of Events
libiguins - Drug Profile
Product Description
Mechanism Of Action
mirabegron ER - Drug Profile
Product Description
Mechanism Of Action
History of Events
PLM-201 - Drug Profile
Product Description
Mechanism Of Action
Recombinant Protein to Agonize CXCR4 for Erectile Dysfunction - Drug Profile
Product Description
Mechanism Of Action
RPCV-1005A - Drug Profile
Product Description
Mechanism Of Action
S1P-205 - Drug Profile
Product Description
Mechanism Of Action
siFi-2 - Drug Profile
Product Description
Mechanism Of Action
History of Events
sildenafil - Drug Profile
Product Description
Mechanism Of Action
History of Events
sildenafil - Drug Profile
Product Description
Mechanism Of Action
History of Events
sildenafil citrate - Drug Profile
Product Description
Mechanism Of Action
sildenafil citrate - Drug Profile
Product Description
Mechanism Of Action
History of Events
sildenafil ODF - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit PDE5 for Erectile Dysfunction - Drug Profile
Product Description
Mechanism Of Action
Stem Cell Therapy for Erectile Dysfunction - Drug Profile
Product Description
Mechanism Of Action
Stem Cell Therapy for Premature Ovarian Failure and Erectile Dysfunction - Drug Profile
Product Description
Mechanism Of Action
SUD-003 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SVF-CLI/ED - Drug Profile
Product Description
Mechanism Of Action
tadalafil - Drug Profile
Product Description
Mechanism Of Action
History of Events
tadalafil - Drug Profile
Product Description
Mechanism Of Action
tadalafil - Drug Profile
Product Description
Mechanism Of Action
History of Events
tadalafil - Drug Profile
Product Description
Mechanism Of Action
History of Events
tadalafil - Drug Profile
Product Description
Mechanism Of Action
tadalafil IR - Drug Profile
Product Description
Mechanism Of Action
History of Events
TF-0092 - Drug Profile
Product Description
Mechanism Of Action
TPN-171 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TPN-729 - Drug Profile
Product Description
Mechanism Of Action
udenafil - Drug Profile
Product Description
Mechanism Of Action
History of Events
vardenafil - Drug Profile
Product Description
Mechanism Of Action
History of Events
vardenafil hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
Yonkenafil - Drug Profile
Product Description
Mechanism Of Action
Erectile Dysfunction - Dormant Projects
Erectile Dysfunction - Discontinued Products
Erectile Dysfunction - Product Development Milestones
Featured News & Press Releases
Mar 03, 2022: CURE Pharmaceutical and Milagro Pharmaceuticals collaborate for registration and approval to sell sildenafil oral thin film in Mexico
Feb 21, 2022: Dicot has identified several new patent opportunities
Dec 21, 2021: European Association of Urology has selected Dicot's study result to be presented
Dec 06, 2021: Dicot's study results will be presented at a leading scientific congress
Dec 02, 2021: Dicot's potency drug candidate demonstrates efficiency and long duration even at a low dose
Nov 16, 2021: CURE Pharmaceutical receives patent approval for Its CUREfilm Blue Technology
Oct 20, 2021: Due to positive study results Dicot publishes a supplement prospectus
Sep 24, 2021: Initiator Pharma includes the first patient in Phase 2b study with IPED2015 in erectile dysfunction patients
Sep 14, 2021: Lukang Pharmaceutical CMS203 tablets obtained the "Notice of Drug Clinical Trial Approval"
Aug 24, 2021: Dicot: Proven long-term effect for Dicot’s drug candidate
Jun 28, 2021: Initiator Pharma receives CTA approval for Phase 2b study with IPED2015 in Erectile Dysfunction patients
Jun 02, 2021: Initiator Pharma - Phase 2a study with IP2018 update
Apr 21, 2021: CURE Pharmaceutical announces successful results from initial clinical trials for erectile dysfunction product CUREfilm Blue
Mar 24, 2021: Dicot begins its first studies on sick animals
Mar 18, 2021: Can-Fite: Topical administration of CF602 fully recovers erectile dysfunction in diabetic model
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Erectile Dysfunction, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Erectile Dysfunction - Pipeline by AnyGen Co Ltd, 2022
Erectile Dysfunction - Pipeline by Aprogen Inc, 2022
Erectile Dysfunction - Pipeline by Aquestive Therapeutics Inc, 2022
Erectile Dysfunction - Pipeline by Arovella Therapeutics Ltd, 2022
Erectile Dysfunction - Pipeline by Astellas Pharma Inc, 2022
Erectile Dysfunction - Pipeline by Autotelic Bio Inc, 2022
Erectile Dysfunction - Pipeline by Benuvia Therapeutics Inc, 2022
Erectile Dysfunction - Pipeline by Biozeus Pharmaceutical SA, 2022
Erectile Dysfunction - Pipeline by Can-Fite BioPharma Ltd, 2022
Erectile Dysfunction - Pipeline by Chengdu Dikang Pharmaceuticals Co Ltd, 2022
Erectile Dysfunction - Pipeline by Cure Pharmaceutical Holding Corp, 2022
Erectile Dysfunction - Pipeline by Dicot AB, 2022
Erectile Dysfunction - Pipeline by Evincis Bio Inc, 2022
Erectile Dysfunction - Pipeline by Exopharm Ltd, 2022
Erectile Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, 2022
Erectile Dysfunction - Pipeline by Farmalider SA, 2022
Erectile Dysfunction - Pipeline by Guangzhou Four-Leaf Clover HealthTech Co Ltd, 2022
Erectile Dysfunction - Pipeline by Hemostemix Inc, 2022
Erectile Dysfunction - Pipeline by Humanetics Corp, 2022
Erectile Dysfunction - Pipeline by ILGEN Inc, 2022
Erectile Dysfunction - Pipeline by Initiator Pharma AS, 2022
Erectile Dysfunction - Pipeline by IntelGenx Corp, 2022
Erectile Dysfunction - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Erectile Dysfunction - Pipeline by Klaria Pharma Holding AB, 2022
Erectile Dysfunction - Pipeline by Lexaria Bioscience Corp, 2022
Erectile Dysfunction - Pipeline by MannKind Corp, 2022
Erectile Dysfunction - Pipeline by Mezzion Pharma Co Ltd, 2022
Erectile Dysfunction - Pipeline by MicroCures Inc, 2022
Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corp, 2022
Erectile Dysfunction - Pipeline by MyX Therapeutics Inc, 2022
Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd, 2022
Erectile Dysfunction - Pipeline by Organicell Regenerative Medicine Inc, 2022
Erectile Dysfunction - Pipeline by Orgenesis Inc, 2022
Erectile Dysfunction - Pipeline by PeLeMed Co Ltd, 2022
Erectile Dysfunction - Pipeline by Pharmicell Co Ltd, 2022
Erectile Dysfunction - Pipeline by Reven Holdings Inc, 2022
Erectile Dysfunction - Pipeline by S1 Biopharma Inc, 2022
Erectile Dysfunction - Pipeline by Seelos Therapeutics, Inc., 2022
Erectile Dysfunction - Pipeline by Shandong Lukang Pharmaceutical Co Ltd, 2022
Erectile Dysfunction - Pipeline by siRNAgen Therapeutics Corp, 2022
Erectile Dysfunction - Pipeline by Targazyme Inc, 2022
Erectile Dysfunction - Pipeline by Tavanta Therapeutics Inc, 2022
Erectile Dysfunction - Pipeline by Techfields Pharma Co Ltd, 2022
Erectile Dysfunction - Pipeline by Tritech Biopharmaceuticals Co Ltd, 2022
Erectile Dysfunction - Pipeline by Venturis Therapeutics Inc, 2022
Erectile Dysfunction - Pipeline by XuanZhu Biological Technology Co Ltd, 2022
Erectile Dysfunction - Pipeline by Yangtze River Pharmaceutical Group, 2022
Erectile Dysfunction - Dormant Projects, 2022
Erectile Dysfunction - Dormant Projects, 2022 (Contd..1)
Erectile Dysfunction - Dormant Projects, 2022 (Contd..2)
Erectile Dysfunction - Discontinued Products, 2022

List of Figures
Number of Products under Development for Erectile Dysfunction, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

Report Title: Erectile Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW